within Pharmacolibrary.Drugs.ATC.V;

model V08CA11
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 9.666666666666666e-07,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.000148,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.000153,
    k12             = 0.246,
    k21             = 0.246
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V08CA11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gadofosveset is a gadolinium-based contrast agent that was used in magnetic resonance angiography (MRA) to enhance blood vessels for improved imaging. It acts as a blood-pool agent due to its reversible binding to serum albumin, resulting in prolonged intravascular retention. Gadofosveset was previously approved for use but has been withdrawn from the US and EU markets over safety considerations and declining usage.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single intravenous injection.</p><h4>References</h4><ol><li><p>Cheng, W, et al., &amp; Zhang, XA (2014). Binding of a dimeric manganese porphyrin to serum albumin: towards a gadolinium-free blood-pool T1 MRI contrast agent. <i>Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry</i> 19(2) 229–235. DOI:<a href=\"https://doi.org/10.1007/s00775-013-1073-6\">10.1007/s00775-013-1073-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24407461/\">https://pubmed.ncbi.nlm.nih.gov/24407461</a></p></li><li><p>Knuttinen, MG, et al., &amp; Xie, KL (2014). Blood Pool Contrast-enhanced Magnetic Resonance Angiography with Correlation to Digital Subtraction Angiography: A Pictorial Review. <i>Journal of clinical imaging science</i> 4 63–None. DOI:<a href=\"https://doi.org/10.4103/2156-7514.145860\">10.4103/2156-7514.145860</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25558430/\">https://pubmed.ncbi.nlm.nih.gov/25558430</a></p></li><li><p>Parmelee, DJ, et al., &amp; Lauffer, RB (1997). Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. <i>Investigative radiology</i> 32(12) 741–747. DOI:<a href=\"https://doi.org/10.1097/00004424-199712000-00004\">10.1097/00004424-199712000-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9406014/\">https://pubmed.ncbi.nlm.nih.gov/9406014</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V08CA11;
